Navigation Links
WuXi PharmaTech Schedules Second-Quarter 2012 Earnings Release
Date:7/11/2012

SHANGHAI, July 11, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the second quarter of 2012 after the New York Stock Exchange closes on Monday, August 13, 2012 (which will be Tuesday morning, August 14, 2012 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com/.

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Tuesday, August 14, 2012, to discuss the second-quarter 2012 financial results and recent business activities. The conference call may be accessed by calling: United States:

1-866-519-4004China (Landline):

800-819-0121China (Mobile):

400-620-8038Hong Kong:

800-930-346United Kingdom:

0-808-234-6646International:

+65-6723-9381Conference ID: 10406942A telephone replay will be available two hours after the call's completion at:

United States:

1-866-214-5335China North:

10-800-714-0386China South:

10-800-140-0386Hong Kong:

800-901-596United Kingdom:

0-800-731-7846International:

+61-2-8235-5000Conference ID:

10406942A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com/.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com
Web: http://www.wuxiapptec.com

 


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Announces Third-Quarter 2011 Results
2. WuXi PharmaTech Named a Top Ten Outsourcing Enterprise in China for Five Consecutive Years
3. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
4. Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call
5. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
6. Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30%
7. ICD-10 Coding Knowledge Assessment Tool Released
8. Verify Brand™ Announces the Release of VB Enterprise 4.0
9. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
10. As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
11. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... May 22, 2017 , ... Baltimore biotech firm, PathSensors, announced ... community in developing and issuing recommendations to grow Maryland's biohealth industry and position ... 2023. , The recommendations are contained in a report from ...
(Date:5/21/2017)... ... 20, 2017 , ... CNSDose is a genetically driven, clinically ... by finding the right antidepressant faster. CNSDose speeds recovery and reduces side ... personalized approach to treatment. , A peer-reviewed and published, 12-week double-blind ...
(Date:5/18/2017)... Mass. (PRWEB) , ... May 18, 2017 , ... ... the procedure on April 28, 2017 at the Prince Of Wales Private Hospital. ... cervical disc at level C6-C7. The patient failed conservative treatments prior to undergoing ...
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl ... CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal ... at Eurofins and Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior ...
Breaking Biology Technology:
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
Breaking Biology News(10 mins):